中国P站

Epigenetics; Cardiovascular Aging; DNA Methylation; Histone Modifications; Non-coding RNAs; MicroRNAs; Therapeutic Targets; Heart Failure; Myocardial Infarction; Myocyte Function

Introduction

Epigenetic mechanisms play a crucial role in regulating various biological processes, significantly impacting cardiovascular health, aging, and disease. These mechanisms, including DNA methylation, histone modifications, and non-coding RNAs, govern gene expression without altering the underlying DNA sequence. A growing body of research highlights their dynamic involvement in the heart and vasculature, offering profound insights into the pathogenesis of age-related cardiac conditions and potential therapeutic avenues. One area of focus is the epigenetic regulation of microRNA (miRNA) expression during cardiac aging. This review delves into how DNA methylation, histone modifications, and non-coding RNAs control miRNA expression and how their dysregulation contributes to age-related cardiac dysfunction and disease. The work suggests that modulating these epigenetic pathways could offer a promising therapeutic strategy to mitigate cardiac aging [1].

Beyond microRNAs, the broader role of epigenetics in cardiovascular diseases, including the aging heart, is a subject of extensive examination. This comprehensive review highlights DNA methylation, histone modifications, and non-coding RNAs, detailing their involvement in critical processes such as cardiac remodeling, myocyte function, and overall cardiovascular health. It provides valuable insights into potential therapeutic targets within these epigenetic pathways [2].

The epigenetic landscape in cardiovascular aging and its progression towards heart failure is another vital area of investigation. Specific changes in DNA methylation and histone modifications are emphasized for their crucial role in myocardial remodeling and cell function. This research indicates that novel epigenetic interventions may effectively combat age-related cardiac decline and its severe consequences [3].

A general overview of epigenetic mechanisms further clarifies their involvement in maintaining cardiovascular health and contributing to disease pathogenesis. These factors undergo significant shifts with age, directly influencing cardiac function and structure, thus underscoring the dynamic nature of epigenetics throughout the lifespan [4].

Many studies offer a broad perspective on the epigenetic underpinnings of various cardiovascular diseases. They specifically examine how DNA methylation and histone modifications change with aging, profoundly impacting myocyte behavior and contributing to conditions such as hypertrophy and fibrosis. Such findings point directly towards the development of targeted epigenetic interventions [5].

Furthermore, current understanding of epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNAs, in the pathogenesis of various cardiovascular diseases is continually evolving. These mechanisms undergo dynamic changes during aging, affecting cardiac cell survival and proliferation, and suggesting new avenues for therapies that could address these age-related alterations [6].

While some research concentrates on specific components, such as endothelial cells, it still provides critical insights into the epigenetic regulation of vascular aging, an essential aspect of overall cardiovascular aging. Discussions reveal how DNA methylation and histone modifications influence cellular senescence and function, indirectly impacting myocardial health and proliferation through their systemic effects [7].

The pursuit of novel epigenetic targets and therapeutic compounds is particularly relevant to conditions like myocardial infarction, which often presents with an aging component. Research in this area highlights how epigenetic modifications influence myocyte survival and repair mechanisms, offering new strategies for promoting cardiac regeneration and mitigating age-related damage after injury [8].

Finally, the role of circulating microRNAs as epigenetic regulators in cardiovascular aging merits specific attention. These small non-coding RNAs, whose expression is often epigenetically controlled, are known to be altered in the aging heart and vasculature. They affect processes such as myocyte growth and senescence, and critically, they serve as potential biomarkers or therapeutic targets, offering a non-invasive window into the aging cardiovascular system [10].

Description

The field of cardiovascular epigenetics is rapidly advancing, offering critical insights into the molecular underpinnings of heart health, aging, and disease. Central to this understanding are epigenetic modifications like DNA methylation, histone alterations, and the regulatory functions of non-coding RNAs. These mechanisms work in concert to modulate gene expression, thereby influencing cellular phenotypes and physiological functions within the cardiovascular system [2, 4]. A significant body of research underscores how the dysregulation of these epigenetic controls directly contributes to the onset and progression of various age-related cardiac pathologies, including heart failure and myocardial infarction [3, 8].

Specific studies have meticulously detailed the intricate relationship between epigenetic mechanisms and microRNA expression in the context of cardiac aging. For instance, alterations in DNA methylation and histone modifications can profoundly affect the transcriptional activity of microRNA genes, leading to an imbalance in their levels. Such imbalances are directly implicated in age-related cardiac dysfunction and disease, suggesting that targeted epigenetic modulation of microRNAs could represent a promising therapeutic strategy to counteract the decline associated with aging hearts [1]. This highlights a crucial area for intervention, as microRNAs are known to regulate a vast array of cellular processes, including cell proliferation, differentiation, and apoptosis, all of which are vital for maintaining cardiac homeostasis.

Furthermore, the epigenetic landscape in the aging heart is complex, involving dynamic shifts that impact myocyte behavior and overall cardiac structure. Changes in DNA methylation patterns and histone acetylation or methylation states are observed to contribute significantly to myocardial remodeling, cellular senescence, and impaired myocyte function [3, 5]. These alterations are not isolated events but rather interconnected pathways that collectively drive pathological changes, such as hypertrophy and fibrosis, commonly seen in aged cardiovascular systems. Understanding these specific modifications provides a molecular blueprint for developing interventions aimed at preserving myocyte integrity and function throughout the aging process [6, 9].

The influence of epigenetics extends beyond the cardiac muscle itself, playing a pivotal role in vascular aging. Research focusing on endothelial cells, for example, illuminates how epigenetic mechanisms, including specific DNA methylation patterns and histone modifications, regulate cellular senescence and function within the vasculature. Since vascular health is intrinsically linked to myocardial health, these insights are crucial for a holistic understanding of cardiovascular aging. The impact on endothelial cell proliferation and overall vascular integrity indirectly, but significantly, affects the heart’s ability to function effectively [7]. Therefore, targeting epigenetic changes in vascular cells could have widespread benefits for preventing age-related cardiovascular diseases.

Another compelling aspect is the emergence of circulating microRNAs as crucial epigenetic regulators and potential biomarkers for cardiovascular aging. The expression levels of these small non-coding RNAs are often under epigenetic control, and their profiles can change dramatically in the aging heart and vasculature. These altered circulating microRNAs affect fundamental processes such as myocyte growth and senescence, making them valuable indicators of physiological age and disease progression. Critically, their accessibility in bodily fluids suggests their potential as non-invasive biomarkers for early detection and as targets for future therapeutic strategies [10]. This opens up new diagnostic and treatment avenues that could revolutionize how we approach age-related cardiovascular conditions.

Lastly, the therapeutic implications of epigenetic research are vast and rapidly expanding. The identification of novel epigenetic targets and the development of compounds that modulate epigenetic enzymes are providing new hope for treating serious conditions like myocardial infarction. By influencing myocyte survival, repair mechanisms, and even promoting cardiac regeneration after injury, epigenetic therapies hold the promise of mitigating age-related damage and improving outcomes in cardiac patients [8]. The overarching theme is clear: epigenetic mechanisms are not just markers of aging and disease but active participants, offering a potent leverage point for future medical interventions.

Conclusion

The scientific literature consistently highlights the profound influence of epigenetic mechanisms on cardiovascular health, aging, and disease. Key epigenetic factors, such as DNA methylation, histone modifications, and various non-coding RNAs, are central to regulating gene expression and cellular processes within the heart and vasculature. Research demonstrates that dysregulation of these mechanisms significantly contributes to age-related cardiac dysfunction, including conditions like heart failure and myocardial infarction. For instance, studies specifically delve into how these epigenetic changes affect microRNA expression in cardiac aging, noting their contribution to age-related cardiac dysfunction and disease, and suggesting that targeting these pathways could be a promising therapeutic strategy. Other comprehensive reviews expand on this, examining the multifaceted role of epigenetics in broader cardiovascular diseases, detailing their involvement in cardiac remodeling, myocyte function, and overall cardiovascular health, thereby identifying potential therapeutic targets. The epigenetic landscape in cardiovascular aging and its progression to heart failure is often emphasized, particularly regarding specific changes in DNA methylation and histone modifications that critically impact myocardial remodeling and cell function. The literature also provides overviews of how epigenetic mechanisms maintain cardiovascular health and contribute to disease pathogenesis, showing how these factors dynamically shift with age, influencing cardiac function and structure. Specific articles explore the epigenetic underpinnings of various cardiovascular diseases, noting how DNA methylation and histone modifications change with aging, affecting myocyte behavior and contributing to conditions such as hypertrophy and fibrosis. This body of work underscores the potential for epigenetic interventions. Even while focusing on endothelial cells, research offers critical insights into the epigenetic regulation of vascular aging, a key component of overall cardiovascular aging, by discussing how DNA methylation and histone modifications influence cellular senescence and function. Furthermore, the potential of circulating microRNAs as epigenetic regulators and biomarkers in cardiovascular aging is discussed, alongside novel epigenetic targets and therapeutic compounds relevant to myocardial infarction, which often involves an aging component. The emerging insights consistently point towards epigenetic modulation as a significant frontier for understanding, preventing, and treating age-related cardiovascular decline.

References

1. Xinchao L, Chun Z, Yahui L (2023) .Front Physiol 14:1184646.

   , ,

2. Jie G, Qiong H, Yuanyuan Y (2023) .Int J Mol Sci 24:9214.

   , ,

3. Shreya S, Nicole JKKT, Daniel JG (2022) .Heart Lung Circ 31:1177-1186.

   , ,

4. Stephanie LK, Michael DCK, Rachel EMK (2021) .Epigenetics Chromatin 14:52.

   , ,

5. Yan Y, Yanyan W, Yuanyuan Y (2023) .Cells 12:1957.

   , ,

6. Kshitij S, Tanupriya C, Mohammad W (2023) .J Clin Med 12:2529.

   , ,

7. Qiong H, Jie G, Yuanyuan Y (2023) .Exp Gerontol 176:112185.

   , ,

8. Yan Y, Yanyan W, Yuanyuan Y (2023) .Phytomedicine 118:154949.

   , ,

9. Wei C, Pengfei H, Yujun S (2022) .Front Cell Dev Biol 10:898444.

   , ,

10. Daniele C, Maria DM, Anna P (2023) .Ageing Res Rev 89:101986.

    , ,